Sarafan ChEM-H
Showing 11-20 of 20 Results
-
Keith Hodgson
David Mulvane Ehrsam and Edward Curtis Franklin Professor of Chemistry and Professor of Photon Science
BioCombining inorganic, biophysical and structural chemistry, Professor Keith Hodgson investigates how structure at molecular and macromolecular levels relates to function. Studies in the Hodgson lab have pioneered the use of synchrotron x-radiation to probe the electronic and structural environment of biomolecules. Recent efforts focus on the applications of x-ray diffraction, scattering and absorption spectroscopy to examine metalloproteins that are important in Earth’s biosphere, such as those that convert nitrogen to ammonia or methane to methanol.
Keith O. Hodgson was born in Virginia in 1947. He studied chemistry at the University of Virginia (B.S. 1969) and University of California, Berkeley (Ph.D. 1972), with a postdoctoral year at the ETH in Zurich. He joined the Stanford Chemistry Department faculty in 1973, starting up a program of fundamental research into the use of x-rays to study chemical and biological structure that made use of the unique capabilities of the Stanford Synchrotron Radiation Lightsource (SSRL). His lab carried out pioneering x-ray absorption and x-ray crystallographic studies of proteins, laying the foundation for a new field now in broad use worldwide. In the early eighties, he began development of one of the world's first synchrotron-based structural molecular biology research and user programs, centered at SSRL. He served as SSRL Director from 1998 to 2005, and SLAC National Accelerator Laboratory (SLAC) Deputy Director (2005-2007) and Associate Laboratory Director for Photon Science (2007-2011).
Today the Hodgson research group investigates how molecular structure at different organizational levels relates to biological and chemical function, using a variety of x-ray absorption, diffraction and scattering techniques. Typical of these molecular structural studies are investigations of metal ions as active sites of biomolecules. His research group develops and utilizes techniques such as x-ray absorption and emission spectroscopy (XAS and XES) to study the electronic and metrical details of a given metal ion in the biomolecule under a variety of natural conditions.
A major area of focus over many years, the active site of the enzyme nitrogenase is responsible for conversion of atmospheric di-nitrogen to ammonia. Using XAS studies at the S, Fe and Mo edge, the Hodgson group has worked to understand the electronic structure as a function of redox in this cluster. They have developed new methods to study long distances in the cluster within and outside the protein. Studies are ongoing to learn how this cluster functions during catalysis and interacts with substrates and inhibitors. Other components of the protein are also under active study.
Additional projects include the study of iron in dioxygen activation and oxidation within the binuclear iron-containing enzyme methane monooxygenase and in cytochrome oxidase. Lab members are also investigating the role of copper in electron transport and in dioxygen activation. Other studies include the electronic structure of iron-sulfur clusters in models and enzymes.
The research group is also focusing on using the next generation of x-ray light sources, the free electron laser. Such a light source, called the LCLS, is also located at SLAC. They are also developing new approaches using x-ray free electron laser radiation to image noncrystalline biomolecules and study chemical reactivity on ultrafast time scales. -
Marie Hollenhorst, MD, PhD
Basic Life Research Scientist, Sarafan ChEM-H
BioDr. Hollenhorst is a physician and scientist with expertise in non-malignant hematology, transfusion medicine, and chemical biology. Dr. Hollenhorst values the one-on-one relationships that she forms with her patients, and strives to deliver the highest quality of care for individuals with blood diseases. Her experience caring for patients drives her to ask scientific questions in the laboratory, where she aims to bring a chemical approach to the study of non-malignant blood disease.
Dr. Hollenhorst pursued combined MD and PhD training at Harvard University, where she received a PhD in Chemical Biology under the mentorship of Professor Christopher T Walsh. She subsequently completed a residency in Internal Medicine at Brigham and Women's Hospital, a fellowship in Transfusion Medicine at Harvard Medical School, and a fellowship in Hematology at Stanford.
Dr. Hollenhorst has an interest in the biology of platelets, which are cellular fragments that help the blood to maintain a healthy balance between bleeding and clotting. Working in the laboratory of Professor Carolyn Bertozzi of Stanford Chemistry, Dr. Hollenhorst is studying sugar molecules found on the surface of platelets that are important in controlling their function and lifespan.
Dr. Hollenhorst's research is supported by an NIH K99 Career Pathway to Independence in Blood Science Award for Physician-Scientists, a Stanford Chemistry, Engineering & Medicine for Human Health Physician-Scientist Fellowship, and a National Blood Foundation Early-Career Scientific Research Grant. -
Michael R. Howitt
Assistant Professor of Pathology and of Microbiology and Immunology
Current Research and Scholarly InterestsOur lab is broadly interested in how intestinal microbes shape our immune system to promote both health and disease. Recently we discovered that a type of intestinal epithelial cell, called tuft cells, act as sentinels stationed along the lining of the gut. Tuft cells respond to microbes, including parasites, to initiate type 2 immunity, remodel the epithelium, and alter gut physiology. Surprisingly, these changes to the intestine rely on the same chemosensory pathway found in oral taste cells. Currently, we aim to 1) elucidate the role of specific tuft cell receptors in microbial detection. 2) To understand how protozoa and bacteria within the microbiota impact host immunity. 3) Discover how tuft cells modulate surrounding cells and tissue.
-
KC Huang
Professor of Bioengineering and of Microbiology and Immunology
Current Research and Scholarly InterestsHow do cells determine their shape and grow?
How do molecules inside cells get to the right place at the right time?
Our group tries to answer these questions using a systems biology approach, in which we integrate interacting networks of protein and lipids with the physical forces determined by the spatial geometry of the cell. We use theoretical and computational techniques to make predictions that we can verify experimentally using synthetic, chemical, or genetic perturbations. -
Ngan F. Huang
Associate Professor of Cardiothoracic Surgery (Cardiothoracic Surgery Research) and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsDr. Huang's laboratory aims to understand the chemical and mechanical interactions between extracellular matrix (ECM) proteins and pluripotent stem cells that regulate vascular and myogenic differentiation. The fundamental insights of cell-matrix interactions are applied towards stem cell-based therapies with respect to improving cell survival and regenerative capacity, as well as engineered vascularized tissues for therapeutic transplantation.
-
Possu Huang
Assistant Professor of Bioengineering
Current Research and Scholarly InterestsProtein design: molecular engineering, method development and novel therapeutics
-
Adrian Hugenmatter
Director of Protein Engineering
BioDr. Adrian Hugenmatter joined ChEM-H in 2021 and is leading the Protein Therapeutics Knowledge Center. In this role he is also responsible for IMAs Protein Therapeutic module. Dr. Hugenmatter received his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Zurich (ETH Zurich, Switzerland), where he gained initial experience in enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he joined the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Afterwards, Dr. Hugenmatter worked as a research scientist and team leader at Roche for more than a decade. During that time, he was involved in the development and optimization several antibody lead candidates for therapeutic applications in Neuroscience and Oncology.
-
Paul S Humphries
Alliance Director, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)